KIF11 targeting agents showed high efficacy in mouse models of cancer, and the kinesin family also suggested promise in combination therapy or in overcoming therapy resistance in cancer.6 We wanted to know whether interfering KIF11 would influence the sensitivity of CRC cells to oxaliplatin, a commonly used chemotherapy drug for CRC patients. The gene discussed is KIF11; the disease is cancer.